Posts by: Alejandra Viviescas, PhD

Alejandra Viviescas, PhD

Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.

June 21, 2019

Pixuvri Gets Full Approval in Europe for Aggressive Non-Hodgkin’s B-cell Lymphomas, Servier Announced

News

The European Commision has converted the conditional approval of Servier‘s Pixuvri (pixantrone) into a standard marketing authorization, allowing the treatment’s use by people with aggressive non-Hodgkin’s B-cell lymphoma whose cancer has ... Read more

April 18, 2019

Velcade Add-on Doesn’t Improve Survival Outcomes in Newly Diagnosed DLBCL, Trial Shows

News

Adding Velcade (bortezomib) to standard chemotherapy is well-tolerated but does not improve the survival outcomes of patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL), even after stratifying patients according to ... Read more

December 11, 2018December 11, 2018

Size Matters: Height May Heighten Risk Factor for Certain Cancers, Study Finds

News

Taller people have a higher risk of developing some types of cancer — including lymphoma — because they have a larger number of cells, according to a University of California, Riverside ... Read more

October 3, 2018

Adcetris-Gemcitabine Combo Eliminates Cancer in Two-thirds of Hodgkin’s Lymphoma Patients in Phase 1/2 Trial

News

A combination of Adcetris (brentuximab vedotin) and the chemotherapy gemcitabine completely eliminated the tumors in two out of three children and young adults with Hodgkin’s lymphoma in a Phase 1/2 ... Read more